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Epstein–Barr Virus (EBV) can infect and transform human B-lymphocytes and has been associated with numerous human
malignancies. Two distinct types of EBV have been described, EBV-1 and EBV-2. Whereas type 1 is known to be most
widespread throughout the healthy adult population, type 2 EBV has been shown to be significantly present in certain T-cell
immunocompromised patients. Some evidence also suggests that such immune impairment promotes coinfection with
multiple strains of EBV and fosters the development of intertypic recombinant viruses. In this work, we have analyzed two
established body-cavity-based lymphoma or primary effusion lymphoma cell lines, BC-1 and BC-2, for the presence of
intertypic EBV recombinants. Using PCR primers to amplify across several markers in the genome, we have typed the BC-1
and BC-2 EBV at these loci. Immunoblot analysis of the EBNA1 protein expressed by these cell lines also suggests a change
in EBV typing at this locus in these genomes. Additionally, we have analyzed the expression patterns of the latent EBNA
proteins from these viruses and performed Southern blot analysis of the BamHI- and EcoRI-digested genomes to detect
variations occurring from type I and II genomes. On the basis of these data, we suggest that the genomes of EBV in BC-1
and BC-2 are intertypic recombinants of type 1 and type 2 EBV genomes. This work corroborates other reports that intertypic
EBV recombinants occur in the immunocompromised population. It is likely that intertypic recombination is a mechanism by
which novel variants of EBV emerge having selective advantages over a strictly type 1 or type 2 strain. © 1999 Academic Press
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tINTRODUCTION
Human Herpesvirus 4, or Epstein–Barr Virus (EBV), is
gammaherpesvirus that infects B-lymphocytes and cer-
ain types of epithelial cells (Kieff, 1996). Most commonly
nown as the etiological agent of infectious mononucle-
sis, EBV can be found in the primary B-cells of the
eripheral blood from the majority of the adult popula-
ion. EBV is associated with a gradual oncogenic pro-
ess and has been linked to several types of human
alignancies, including Burkitt’s lymphoma, nasopha-
yngeal carcinoma, Hodgkin’s Disease, and various im-
unoblastic lymphomas (for review, see Rickinson,
996). EBV typically establishes latent infection in resting
-lymphocytes. The complete set of latent transcripts
ncludes Epstein–Barr virus nuclear antigens (EBNA) LP,
, 2, 3A, 3B, and 3C; latent membrane proteins (LMPs) 1,
A, and 2B; the Epstein–Barr virus early RNAs (EBERs);
nd the BARF0 transcripts (Mannick et al., 1991; Sample
t al., 1991; Tomkinson and Kieff, 1992b; Kaye et al., 1993;
omkinson et al., 1993a; Izumi et al., 1997).
Two distinct types of EBV have been isolated and
haracterized. Originally designated as A or B, these two
1 To whom reprint requests should be addressed at Department of
icrobiology and Immunology, University of Michigan Medical School,
nn Arbor, Michigan, 48109-0620. Fax: (734) 764-3562. E-mail:
(srobert@umich.edu.
359ifferent viral types are now referred to as type 1 or 2 in
eeping with the herpes simplex system of nomenclature
Rickinson, 1996). Even though type 1 and type 2 EBV are
argely the same throughout most of the genome, the
iral genomes can be typed based on known polymor-
hisms in the latent genes EBNA2, 3A, 3B, and 3C. These
enes differ in their predicted primary amino acid se-
uence by 47, 16, 20, and 28%, respectively (Dambaugh
t al., 1984; Adldinger et al., 1985; Sample et al., 1990;
ieff, 1996). The EBNA loci can be typed by previously
stablished techniques at the nucleotide level by PCR
Sample et al., 1990) or less conclusively at the protein
evel by the type-specific reactivity of EBNA epitopes with
uman sera (Rowe and Clarke, 1989; Rowe et al., 1989;
culley et al., 1989).
Virus isolation studies of EBV derived from healthy
atients have demonstrated that type 1 EBV is most
revalent in these individuals, with EBV-1 being the only
irus type present in $90% of the examined cases (Yao et
l., 1991, 1998; Gratama et al., 1994). However, virus
solation studies of certain T-cell-immunocompromised,
IV-positive cohorts have shown that type 2 EBV exists
n much greater proportion in these groups (Sculley et al.,
990; Buisson et al., 1994; Yao et al., 1996a,b, 1998). In
ome HIV-positive homosexuals, EBV-2 has been shown
o be substantially present in .30% of the patients tested
Yao et al., 1996b, 1998). The predominance of a single
0042-6822/99 $30.00
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360 AGUIRRE AND ROBERTSONransforming virus strain, most commonly EBV-1 rather
han EBV-2, has been demonstrated in healthy individu-
ls; however, increasing evidence suggests that multiple
BV infections are common within immunocompromised
osts (Katz et al., 1986; Sculley et al., 1990; Yao et al.,
991, 1996b). In one study of a T-cell-immunocompro-
ised HIV-positive cohort, 17 of 35 patients demon-
trated coinfection with multiple strains of EBV, and 9 of
hese 17 individuals proved to be coinfected with both
ype 1 and type 2 strains of EBV (Yao et al., 1996b). In
ddition, type 1/type 2 EBV coinfection has been dem-
nstrated in patients with HIV-associated oral hairy leu-
oplakia (HLP) (Walling et al., 1992) and in lymph node
iopsies of patients with Hodgkin’s Disease (HD) and
on-Hodgkin’s lymphoma (Bouzid et al., 1993).
The discovery of coinfecting strains and types of EBV
rompts the question of whether recombination occurs
etween two EBV genomes coinfecting the same cell.
aboratory experiments have shown that type 1 and type
EBV can undergo recombination resulting in an EBV
ecombinant that demonstrates wild-type transforming
unctions (Skare et al., 1985; Tomkinson et al., 1993b).
BV coinfection and recombination has been shown to
e common in HLP lesions, regardless of immune status
Walling and Raab-Traub, 1994; Walling et al., 1994, 1995).
type 1/type 2 EBV recombinant has been isolated from
healthy adult from Papua New Guinea (Burrows et al.,
996). Furthermore, another study has demonstrated the
xistence of naturally occurring EBV intertypic recombi-
ants in 2 of 40 analyzed HIV-positive T-cell-immunocom-
romised patients (Yao et al., 1996a). The discovery of
uch naturally occurring intertypic recombinants sug-
ests the emergence of novel infectious strains of Ep-
tein–Barr Virus that warrant further study.
In this study, we have examined two AIDS-related
ody-cavity-based lymphoma cell lines (AIDS-BCBLs),
C-1 and BC-2 (Cesarman et al., 1995). Previously pub-
ished work suggested that BC-1 contains EBV-2,
hereas BC-2 contains EBV-1 (Horenstein et al., 1997).
owever, we provide evidence for a different model for
he EBV strain infecting BC-1 and BC-2. Using PCR typing
ssays as well as Western and Southern blots, we have
emonstrated that these transformed cell lines harbor
otential intertypic recombinants of type 1 and type 2
pstein–Barr Virus. This work provides an important ex-
mple of intertypic recombination and summarizes an
ffective series of typing experiments that can be used in
uture studies.
RESULTS
nalysis of the viral genomes in BC-1 and BC-2
To examine the genome type of the BC-1 and BC-2
irus, we analyzed five different genomic markers (Fig. 1).
he analyzed loci are widely distributed across the EBV
enome and provide five possible regions within which tecombination can be identified. We used PCR primers
pecific for five different loci (see Table 1) and immuno-
lot analysis to type the sixth marker. In addition we have
sed Southern blot analysis to demonstrate restriction
ragment differences among BC-1, BC-2, P3HR-1, and
95-8. Although previous work has suggested that BC-1
nd BC-2 EBV were type 2 and type 1, respectively
Horenstein et al., 1997), the data from our experiments
emonstrate that type 1/type 2 recombination had oc-
urred to form the intertypic EBV recombinants in the
C-1 and BC-2 cell lines.
CR typing assays demonstrate that sequences from
oth EBV type 1 and 2 are present in BC-1 and BC-2
The first marker we examined is located adjacent to
he Epstein–Barr Virus early RNAs (EBERs). An AluI site
s located at 6913 bp in the prototypic type 1 EBV ge-
ome. PCR primers amplified a 157-bp fragment in both
he standard type 1 (B95-8) and type 2 (P3HR-1) viral
enomes, as well as in both the BC-1 and BC-2 viruses
Fig. 2A). However, digestion of the PCR product with AluI
ccurs only in B95-8 (type 1) DNA, and not in P3HR-1
type 2) DNA (Baer et al., 1984; Arrand et al., 1989) (Fig.
B). AluI digestions of the B95-8 and P3HR-1 PCR prod-
cts were compared with AluI digestions of the viral DNA
n BC-1 and BC-2 (Fig. 2B). Digestion of BC-1 or BC-2
ields only one band that migrates at the same size as
FIG. 1. Schematic of the EBV episome, indicating the genomic loca-
ion of the latently expressed genes. Note also the location of the PCR
rimers and restriction sites used in the typing assays. The shaded
reas indicate deleted regions identified in B95-8, Raji, and P3HR-1
trains (Kieff, 1996).he undigested P3HR-1 band, consistent with the ab-
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361INTERTYPIC EBV RECOMBINANTS IN BC-1 AND BC-2ence of an AluI site at 6913 bp in both the BC-1 and
C-2 viral genomes. These results suggest that BC-1 and
C-2 are type 2 EBV at the 6913-bp locus.
PCR analysis also allows distinction between type-
pecific polymorphisms in the EBNA2 gene, which is
T
Primer Sets Used for Analysis of the EBV Genomes U
Primer location Nucleotide sequence (59-39)
AluI-6913 acgttgcatcccagaagatg
gtcggtagcaccgcactgag
EBNA2 gggatgcctggacacaagag
ctcggttgtgacagaggtgac
gccttggtggtattatcagtg
EBNA3B tttgaggttatgcgtgcggt
tggactttatctccccctgt
ctaggcagtttattccttga
EBNA3C agaaggggagcgtgtgttgt
ggctcgtttttgacgtcggc
BamHI-122 agcgcatggccggcatctgag
attcttgcagtggtgccggag
Note. The table shows the specific sequences used in the analysis
equence except in the case of the EBNA2 and EBNA3B primer sets w
FIG. 2. PCR and restriction endonuclease analysis for the presence
f an AluI restriction site at the 6913-bp locus in the EBV genome. The
rimers flanking the AluI site at 6913 bp in the B95-8 genome amplify a
57-bp fragment in both the B95-8 and P3HR-1 controls. However, only
he type 1 B95-8 PCR fragment can be digested into two smaller
ragments due to the presence of an AluI restriction site at 6913 bp. (A)
hows the undigested PCR products, whereas (B) shows the results of
igesting the PCR-amplified product with AluI. (B) clearly demonstrateshat both BC-1 and BC-2 are type 2 at this locus. tocated downstream of the EBERs in the BamHI YH
egion of the genome (Dambaugh et al., 1984; Adldinger
t al., 1985). PCR reactions using a three-primer mix with
common 59 primer and type-specific 39 primers (Sam-
le et al., 1990) yielded different amplification products
or B95-8, the prototypic type I, and Jijoye (Miller et al.,
974; Baer et al., 1984), a prototypic type II virus (Fig. 3).
hen BC-1 and BC-2 were amplified with the EBNA2
rimer mix, the BC-1 reaction yielded the same size band
s the Jijoye, indicating that BC-1 virus was type 2 at this
ocus. The BC-2 reaction, however, gave a band that
igrated at the same position as the band in the B95-8
ane (Fig. 3). Thus the BC-2 virus can be identified as type
Determination of Regions That Are Type 1 or Type 2
Product size (bp) Reference
T1: 157 Sample et al., 1990
T2: 157 Tomkinson et al., 1993b
T1: 252 Sample, 1990
T2: 218 Tomkinson et al., 1993b
T1: 183 Sample, 1990
T2: 218 Tomkinson et al., 1993b
T1: 153 Sample, 1990
T2: 246 Tomkinson et al., 1993b
T1: 249 Heller et al., 1981
T2: 249 Tomkinson et al., 1993b
e size of the PCR product made. Sequences are based on the B9-58
third primer from the type 2 sequence was used in the analyses.
FIG. 3. PCR analysis of type 1 and type 2 polymorphisms in the
BNA2 gene. The B95-8 genome is the type 1 control (Baer et al., 1984).
ijoye is the P3HR-1 parental cell line and is infected with type 2 EBV
Miller et al., 1974). BJAB is an EBV negative cell line, and the PO lane
epresents the primers only control with no DNA template added. The
C-1 EBNA2 PCR product migrates at the same rate as the type 2 Jijoye
ontrol, whereas the BC-2 EBNA2 PCR product migrates consistently
ith the type 1 B95-8 control. Thus BC-1 is type 2 and BC-2 is type 1 atABLE 1
sed in
and thhis locus.
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362 AGUIRRE AND ROBERTSONat the EBNA2 locus. Although the BC-1 virus proved
onsistent for type 2 sequence through the first two loci,
he switch from type 2 to type 1 in BC-2 EBV provided
vidence consistent with the occurrence of an intertypic
ecombination between the AluI locus and the EBNA2
ocus.
Type 1 and type 2 polymorphic loci of the EBNA3B and
C genes, located downstream of EBNA2, also lend
hemselves to effective PCR typing analysis (Sample et
l., 1990; Tomkinson and Kieff, 1992b; Tomkinson et al.,
993a). Here we have used primers specific for these
enes to show differences in the amplification products
or the type 1 and type 2 alleles (Fig. 4). PCR reactions of
he BC-1 EBNA3B and 3C genes yield amplification prod-
cts that migrate the same distance as those from PCR
eactions of the P3HR-1 EBNA3B and 3C genes (Fig. 4).
his indicates that the BC-1 viral genome is consistent
ith type 2 sequences at these markers. BC-2 EBNA3B
nd 3C PCR products demonstrate that the BC-2 virus
ontain sequences of a typical type 1 virus at these loci.
hus the BC-2 EBNA2, 3B and 3C genes appear to all
emonstrate type 1 characteristics at the nucleotide
evel.
Using primers that amplify from nucleotides 122,206 to
FIG. 4. PCR analysis of type 1 and type 2 polymorphisms within the
BNA3B and 3C genes. EBNA3B primers amplify a 218- or 183-bp
ragment from type 2 or type 1 EBV, respectively. EBNA3C primers
mplify a 246- or 153-bp fragment from type 2 or type 1 EBV, respec-
ively. (A) shows PCR analysis of the EBNA3B locus, whereas (B) shows
CR analysis of the EBNA3C locus. Each panel contains the B95-8 (T1),
3HR-1 (T2), BJAB (EBV-), and PO (primers only) controls. BC-1 is clearly
ype 2 at both loci, whereas BC-2 is type 1 at both of these markers.22,475, we analyzed the BC-1 and BC-2 genomes for the Tresence of a BamHI restriction site within this fragment.
he prototypic type I virus has been shown to have a
amHI restriction site within this PCR product, whereas
n the type II virus DNA, this restriction site has been
hown to be absent (Fig. 5) (Heller et al., 1981; Baer et al.,
984). BamHI digestion of the BC-1 and BC-2 PCR prod-
cts demonstrated that both viruses possess the restric-
ion site within the amplification fragment. These results
uggest that BC-1 and BC-2 are both type 1 virus at this
ocus. Thus our data are consistent with the possibility
hat intertypic recombination occurred in the region be-
ween the EBNA3C and BamHI 122-kb markers within
he BC-1 virus.
estern blot analysis for detection of the latent
BNA proteins indicates that the electrophoretic
obility of EBNA1 is similar in BC-1 and BC-2
In an effort to further characterize the BC-1 and BC-2
ntertypic recombinants, we analyzed the electrophoretic
obility of the EBNA proteins from BC-1 and BC-2 vi-
uses to determine its “EBNA type” (Yao et al., 1991). Type
(B95-8) and type 2 (P3HR-1) EBNA proteins demon-
trate characteristically unique electrophoretic mobilities
n an SDS–PAGE gel, as can be demonstrated by immu-
oblot analysis with a human sera containing cross-
FIG. 5. PCR and restriction endonuclease analysis for the presence
f a BamHI restriction site at the 122-kb locus. (A) and (B) show the
ndigested and digested PCR products, respectively. Type 1 B95-8 and
ype 2 P3HR-1 controls are shown. BJAB (BJ) is an EBV-negative cell
ine. Only type 1 EBV contains the BamHI site at the 122-kb locus. Both
C-1 and BC-2 Bam122kb PCR products can be digested with BamHI.
hus BC-1 and BC-2 are type 1 at this locus.
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363INTERTYPIC EBV RECOMBINANTS IN BC-1 AND BC-2eactive antibodies for both type 1 and type 2 EBNAs
Fig. 6, lanes 3 and 4) (Yao et al., 1991). Cell lysates from
he BC-1 and BC-2 cell lines were fractionated and an-
lyzed by Western blot using human serum that detects
BNA1 from type I and type II donors. The results
howed that EBNA1 from BC-1 and BC-2 both migrated
t about the same position (Fig. 6, lanes 1 and 2). More
mportantly, however, comparison of the EBNA1 bands
rom BC-1 and BC-2 with those from B95-8 and P3HR-1
ndicated that BC-1 and BC-2 EBNA1 both migrate similar
o that of the type 2 EBNA1 from P3HR-1 (Fig. 6, lanes
–4). The uniformity in size of EBNA1 from the BC-1, BC-2,
nd the type 2 P3HR-1 viruses suggests that the BC-1
nd BC-2 EBV genomes are consistent with type 2 at this
ocation. However, EBNA1 can vary in size due to the
epeated elements within the open reading frames (Kieff,
996), but variations in sizes of EBNA1 protein are usu-
lly seen with bands migrating faster on gels (Yao et al.,
991). Typically the type 1 EBNA1 proteins uniformly
igrate slower than the type 2 EBNA1 proteins, suggest-
ng that EBNA1 signals from type 1 and type 2 viruses
an be distinguished. On the basis of this data, we
uggest that BC-1 and BC-2 EBNA1 proteins are consis-
ent with type 2 genomic DNA.
To characterize expression of the other latent EBNA
roteins, BC-1 and BC-2 were analyzed by Western blot
sing human serum that recognizes EBNALP, 1, 2, 3A, 3B,
nd 3C (Fig. 7). To account for low levels of gene expres-
ion in the BC-1 and BC-2 cell lines, twice as many cells
1,000,000 cells) were harvested as compared with the
FIG. 6. Immunoblot analysis using human serum specific for EBNA1
ecognition. Cross-reactive antibodies to EBNA1 recognized both type
and type 2 variants of the protein. Type 1 B95-8, type 2 P3HR-1, and
BV-negative BJAB controls are shown. Both BC-1 and BC-2 EBNA1
igrate at a rate more consistent with type 2 EBNA1 from the P3HR-1
ell line. The type-specific electrophoretic mobility of the BC-1 and
C-2 EBNA1 proteins suggest that both BC-1 and BC-2 are type 2 at the
BNA1 locus in the genome.95-8, P3HR-1, and BJAB controls (500,000 cells). The besults of this experiment demonstrate that BC-1 and
C-2 do not express the EBNA3 proteins (Fig. 7, lanes 2
nd 3). Furthermore these cell lines do not express the
BNA2 protein, a result consistent with previous reports
Fig. 7, lanes 1 and 2) (Horenstein et al., 1997; Szekely et
l., 1998). However, more specific analysis would have to
e done to demonstrate changes in expression patterns
ccurring in BC-1 and BC-2 over time. Therefore we
uggest that based on previous reports in analysis of
BV genomes for type I and type II, the BC-1 and BC-2
BV genomes are consistent with that seen for intertypic
irus recombinants. By combining our data from Western
lot analyses with that from the PCR assays, we have
eveloped a type map of the EBV genome at five different
oci. These results are summarized in Table 2.
outhern blot analysis detects the presence of
enomic variations in BC-1 and BC-2
DNA from the BC-1 and BC-2 cell lines was digested
ith BamHI and EcoRI restriction endonucleases and
robed with total EBV DNA. Southern blot analyses are
hown in Fig. 8. Previous work has characterized the
FIG. 7. Immunoblot analysis for latent EBNA expression. Latent
BNA proteins are labeled. Type 1 B95-8, type 2 P3HR-1, and EBV-
egative BJAB controls are also shown. BC-1 and BC-2 both express
he EBNA1 protein. Note specifically the presence of EBNA2 expres-
ion in B95-8 but the absence of expression of this protein in BC-1,
C-2, and P3HR-1 (deleted for EBNA2). This result is similar to previous
nalyses, although changes in expression patterns of the BC-1 and
C-2 cell lines can occur after long-term passage in culture. EBNALP
s seen in B95-8 and P3HR-1. Faint signals in BC-1 and BC-2 are from
onspecific signals, which do not react with specific monoclonal anti-
ody against EBNALP.
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364 AGUIRRE AND ROBERTSONamHI restriction maps of the B95-8 and P3HR-1 EBV
enomes (Baer et al., 1984; Dambaugh et al., 1984; Rob-
rtson and Kieff, 1995; Robertson et al., 1994). Compari-
on of the restriction patterns of the BC-1 and BC-2 EBV
ith those of the B95-8 and P3HR-1 controls indicates
enomic variations occurring in BC-1 and BC-2. A thor-
ugh analysis of the restriction fragments shown on
hese Southern blots would require verification through
robing with DNA from the known BamHI restriction
ragments in question. Because such an examination is
ot the scope of this paper, we will limit our analysis of
he blot presented to a general commentary on evidence
hat supports the idea that BC-1 and BC-2 EBV are
ctually T1/T2 chimeras and not wild-type complements
f type 1 or type 2.
Southern blot of BamHI-digested DNA from the LCLs
sing the total EBV probe demonstrated important
enomic variations in the BC-1 and BC-2 genomes (Fig.
). Whereas some bands in the BC-1 and/or BC-2 lanes
ave corresponding bands in the B95-8 and/or P3HR-1
anes, other bands do not correspond to either the B95-8
r P3HR-1 controls. These unique changes in banding
atterns have been indicated with arrows in bold to the
ight of the image. It is possible that recombination
vents have created new restriction fragment polymor-
hisms in these viral genomes. Such findings inevitably
omplicate the analyses presented here but demon-
trate that potential recombination events had occurred
n these viral genomes.
The first arrow (from the top of Fig. 8) denotes a band
n the BC-1 lane that corresponds to the type-2-specific
G fragment. This band is absent in the BC-2 lane, which
as type 1 EBNA sequences by PCR analysis. The sec-
nd arrow indicates a band present in the BC-2 lane that
orresponds to the BamA fragment in the B95-8 genome.
his band does not appear in the BC-1 lane. The third
rrow indicates the BamHI-G band in the B95-8 genome.
his band does not appear in the P3HR-1 genome or in
ither BC-1 or BC-2. The fourth arrow indicates the pres-
nce of the BamHI-H fragment in the B95-8 genome. This
ragment does not appear in any of the other cell lines.
T
Classification of EBV Gen
Cell line
Genom
AluI-6913bp EBNA 2
B95-8 T1 T1
Jijoye/P3HR-1 T2 T2
BC-1 T2 T2
BC-2 T2 T1
Note. Summary of data from EBV genomic typing experiments indic
ostly T2 with T1 sequences at the right end of the genome. BC-2 isABLE 2
ome Type at Six Different Loci
ic marker [type 1 (T1) or type 2 (T2)]
EBNA 3B, 3C EBNA 1 BamHI-122kb
T1, T1 T1 T1
T2, T2 T2 T2
T2, T2 T2 T1
T1, T1 T2 T1
ating regions where type 1 or type 2 EBV sequences are identified. BC-1 ishe fifth band denotes the BamHI-I or Jhet bands in the eFIG. 8. Southern blots of DNA from BC-1 and BC-2 cell lines. The
95-8 cell line is infected with type 1 EBV (Baer et al., 1984), and the
arental P3HR-1 cell line harbors type 2 virus (Miller et al., 1974). DNA
as digested with BamHI and probed with total EBV DNA. BamHI
estriction maps of B95-8 and P3HR-1 were previously described (Rob-
rtson and Kieff, 1995). Arrows indicate positions of bands that repre-
ent genomic variations within the BC-1 and BC-2 EBV genomes. The
resence of such bands demonstrates that potential recombination
vents had occurred in these viral genomes.
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365INTERTYPIC EBV RECOMBINANTS IN BC-1 AND BC-295-8 and P3HR-1 genomes. BC-1 appears to have a
ype 2 band at this location while BC-2 appears to have
type 1 band. The sixth arrow indicates what could
epresent the S, T, U, or V bands. In the BC-1 and BC-2
anes, the band at this approximate location appears to
e migrating faster than these bands in the B95-8 or
3HR-1 lanes.
These analyses therefore are consistent with genomic
ariations occurring in BC-1 and BC-2 EBV strains. More-
ver, they support the PCR analyses in the conclusion
hat the EBV genomes infecting the BC-1 and BC-2 cell
ines are intertypic recombinants. Further studies will
etermine the precise location of these recombination
vents.
DISCUSSION
Our findings suggest that the EBV infecting the BC-1
nd BC-2 cell lines are intertypic recombinant viruses.
CR analysis of type-specific polymorphisms within the
BNA2 and EBNA3B and 3C genes has enabled us to
lassify these loci as type 1 or type 2 in the BC-1 and
C-2 viruses. In addition, studies of the PCR-amplified
ragments at two markers (AluI-6.9kb; BamHI-122kb) with
he typical type I restriction site (Robertson and Kieff,
995; Tomkinson et al., 1993b) have allowed us to further
haracterize the viral genomes. Western blotting analysis
f the EBNA1 protein expressed in these cell lines also
as enabled us to suggest a type-specific electro-
horetic mobility of the BC-1 and BC-2 EBNA proteins
results summarized in Table 2).
Western blots to analyze expression of the latent
FIG. 9. Recombination maps of the BC-1 and BC-2 EBV genomes. Ou
f the EBNA1 marker in the BC-1 virus, which is type 2 for most of the
ultiple intertypic recombination events to give a chimeric genome th
in the EBNA1 region but type 1 in the region between the EBNA1 gen
rom intertypic recombination events and from derivation of new strainBNA proteins have demonstrated interesting differ- tnces in the latent gene expression patterns of the BC-1
nd BC-2 EBV. Expression of EBNA3A, 3B, and 3C from
hese cell lines was substantially lower than that of the
ontrols and proved undetectable by SDS–PAGE and
estern blotting. In addition, BC-1 and BC-2 did not
xpress detectable levels of EBNA2. These data are
onsistent with previous analyses for the latent EBNA
roteins that were performed with the BC-1 and BC-2 cell
ines (Horenstein et al., 1997; Szekely et al., 1998). How-
ver, there are changes that occur in latent gene expres-
ion over time in culture. Therefore, we will be continuing
nalyses of these cell lines for changes in expression
atterns with multiple passages in culture. Considering
he importance of the EBNA2 gene to EBV-induced B-
ymphocyte growth transformation (Rickinson et al.,1987;
ooney et al., 1989; Cohen et al., 1991), this observation
hat neither BC-1 nor BC-2 expresses EBNA2 is an im-
ortant and relevant finding to growth and transformation
ssays that will be important in determining variations in
henotype mediated by these viruses.
Southern blotting analysis indicated different restric-
ion fragment length polymorphisms (RFLPs) within the
C-1 and BC-2 genomes, suggesting that these viruses
re intertypic recombinants. Although only a general
nalysis of the observed restriction patterns in the BC-1
nd BC-2 genomes is presented, the data clearly illus-
rates variation of the fragments from those usually seen
n a completely type 1 (B95-8) or type 2 (P3HR-1) virus.
urther Southern blot analysis of the BC-1 and BC-2 EBV
ill enable us to better explain fragment differences
etween these intertypic recombinant viruses and the
uggest that intertypic recombination occurred in a region downstream
e and type 1 at the right end. BC-2 EBV appears to have undergone
e 2 at the left end and type 1 at the right end. BC-2 EBV is also type
the AluI-6913bp marker. These results are consistent with those seen
e population.r data s
genom
at is typ
e andype 1 and type 2 controls. Probing the BamHI-digested
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366 AGUIRRE AND ROBERTSONNA with individual established BamHI fragments will
llow us to determine the specific regions where recom-
ination occurred.
Compilation of the data presented in this work has
nabled us to develop a putative recombination map for
he EBV genome in BC-1 and BC-2 cell lines (Fig. 9).
fficient recombination between type 1and type 2 viruses
lso has been demonstrated in vitro (Tomkinson et al.,
993b; Robertson and Kieff, 1995). On the basis of our
ata, we suggest that the BC-1 EBV genome is consis-
ent with that of type 2 EBV throughout most of the
enome. However, a type 1/type 2 recombination event
ccurred in the region between the EBNA1 and BamHI
22-kb markers; thus, the BC-1 EBV genome switches
rom type 2 to type 1 at a site of recombination that lies
ithin this region. The BC-2 EBV appears to have under-
one multiple recombination events, leaving multiple chi-
eric regions in the genome at which a switch in
enomic type occurs. Our data suggest that recombina-
ion events occurred between the AluI-6913bp marker
nd the EBNA2 locus as well as in regions adjacent to
he EBNA 1 gene. Essential to our analysis and detection
f intertypic recombination was the use of the AluI-
913bp and BamHI-122kb markers, which are located at
pposite ends of the genome and indicate regions of
rototypic type 1 or type 2 sequences (Tomkinson et al.,
993b; Robertson and Kieff, 1995). The known polymor-
hisms in the EBNA1, 2, 3A, 3B, and 3C genes alone
ould not have enabled us to detect recombination
vents in regions flanking the EBNA genes. Although our
ethods were sufficient for identification of intertypic
ecombination in these viruses, use of more typing mark-
rs and further analysis of the EBV genomes from these
ell lines may indicate even more intertypic recombina-
ion events and would enable us to more accurately
dentify the locations of recombination.
Intertypic recombination in EBV first was demon-
trated in the laboratory (Skare et al., 1985; Tomkinson et
l., 1993b). The discovery of EBV intertypic recombinants
n the wild first occurred in two separate studies when
urrows and colleagues and Yao and colleagues iso-
ated intertypic recombinants of EBV from patients and
howed that recombination had occurred within the re-
ion between the EBNA2 and EBNA3A loci (Burrows et
l., 1996; Yao et al., 1996a). We have now provided data
rom two AIDs-BCBLs suggesting that intertypic recom-
ination in the wild can and does occur in other regions
f the EBV genome. By showing that intertypic recombi-
ation occurs at various places throughout the EBV ge-
ome, we have substantiated the claim that chimeric
ariants of type 1 and type 2 EBV exist naturally. Further-
ore we present the first example showing that inter-
ypic EBV recombinants exist in these two cell lines,
C-1 and BC-2. These intertypic recombinants may have
een derived from coinfection at the cellular level, eithern the original host or in the process of isolating the cell rine. We have shown that the intertypic recombinants
nfecting the BC-1 and BC-2 cell lines are the only strains
f EBV present in these cell lines. Whether these chi-
eric variants can confer the transforming phenotype on
he host cells to efficiencies comparable with that from
ild-type EBV will be explained in future studies. Regard-
ess, the multitude of EBV-associated malignancies al-
udes to the importance of the discovery of transformed
ymphocytes harboring intertypic recombinant EBV.
The discovery of intertypic recombinants provokes nu-
erous hypotheses regarding the significance of such
indings. Intertypic recombinant variants of EBV may in-
icate an evolutionary mechanism for the emergence of
ovel infectious strains of this virus. Combinations of
henotypes conferred by either type 1 or type 2 viruses
nd/or new phenotypes generated by such recombina-
ion events may serve to alter the viruses’ infectious
apacity and/or transforming ability. Furthermore, altered
ropisms for various host cells may increase the host
ange and virulence of these recombinant variants. Type
/type 2 EBV chimeras also may exhibit novel mecha-
isms of immune evasion. Changes in patterns of gene
xpression or alterations in programs of EBV latency
ay enable these recombinant variants to elude estab-
ished immune responses to EBV infection. Immune re-
ponse to antigenic properties of the widely prevalent
ype 1 virus may prove ineffective against the antigenic
haracteristics of newly emerging intertypic recombi-
ants, which could, at least in part, encode for the less
revalent proteins expressed by the type 2 EBV genome.
ence, new combinations of type 1 and type 2 EBV
ntigens could result in an increase in transformation
fficiency as well as an enhancement of the ability of
BV to evade T-cell surveillance.
Increased evidence for the prevalence of type 2 EBV in
ome HIV-positive T-cell-immunocompromised hosts
long with data suggesting a greater frequency of mul-
iple EBV infections in these patients (Yao et al., 1996b,
998) have promoted interest in the epidemiology and
haracteristics of type 1 and type 2 EBV infection. Con-
equently, the discovery of intertypic recombinants in the
opulation has shed light on what may be an emerging
rend in EBV infection and evolution. A single dominant
nfecting strain is probably present in the majority of the
ealthy population. However, the number of patients with
mmune impairment disorders, such as AIDS, continues
o increase. It has been shown that immunocompro-
ised patients exhibit a high degree of EBV replication
nd shedding of virions within the oropharynx (Strauch et
l., 1974; Alsip et al., 1988; Walling and Raab-Traub, 1994).
ncreased levels of EBV as well as impaired T-cell im-
une surveillance may contribute to a rising incidence of
ype 1/type 2 co-infection (Yao et al., 1996b). T1/T2 coin-
ection at the cellular level leads to a higher probability
or the occurrence of recombination events. Intertypic
ecombinants may emerge with a selective advantage
d
m
v
E
o
o
m
r
s
a
s
t
v
T
h
A
d
i
a
a
a
d
K
J
1
p
P
a
w
E
m
R
v
p
P
m
a
d
E
(
s
B
a
A
a
c
b
t
B
(
1
a
p
(
D
t
w
P
(
e
t
p
c
m
p
p
t
e
m
t
N
F
r
p
o
z
I
s
e
t
i
n
l
s
s
0
b
p
t
w
t
I
f
S
w
p
367INTERTYPIC EBV RECOMBINANTS IN BC-1 AND BC-2ue to enhanced transforming ability and/or better im-
une evasion mechanisms. Consequently, these novel
iruses may increase the host range and virulence of
BV.
The emergence of type 1/type 2 recombinant variants
f EBV may have important implications for the treatment
f EBV-associated malignancies; thus it is important to
onitor the evolutionary progression of these intertypic
ecombinants and to further characterize such novel
trains. Typing experiments must be continued to more
ccurately and thoroughly describe other emerging EBV
trains. Experiments testing the infectious capacity and
ransformation efficiency of the intertypic recombinant
iruses in BC-1 and BC-2 also have been performed.
hese data will further address the issues discussed
ere.
MATERIALS AND METHODS
ntibodies and cell lines
Latent EBNA proteins were analyzed using antibodies
erived from a patient serum previously characterized for
dentification of each of the EBNA proteins (Robertson
nd Kieff, 1995). Serum samples were adsorbed against
n EBV-negative Burkitt’s lymphoma cell line BJAB lysate
t 4°C for 48 h. Adsorbed serum was then used as a 1:50
ilution in PBS with 1 mM sodium azide.
BJAB is an EBV-negative cell line obtained from Elliott
ieff. The B95-8 cell line harbors type I EBV, and the
ijoye cell line is infected with type II EBV (Miller et al.,
972, 1974). The P3HR-1 cell line is derived from its Jijoye
arent, and also contains type II EBV; however, the
3HR-1 genome is deleted for regions in the EBNALP
nd EBNA2 genes (Rabson et al., 1982). BC-1 and BC-2
ere purchased from the ATCC and are coinfected with
BV and KSHV (Horenstein et al., 1997). Cell lines were
aintained in complete medium, which consisted of
PMI 1640 supplemented with 15% inactivated fetal bo-
ine serum, 2 mM glutamine, and 10 mg of Gentamicin
er milliliter.
olymerase chain reaction (PCR) analyses.
PCR Primers. Primers corresponding to four different
arkers in the EBV genome were used in the PCR typing
nalyses (Fig. 1). The primer combinations that amplify
istinctive type 1 and type 2 EBV fragments for the
BNA3B and 3C genes have been previously described
Sample et al., 1990; Tomkinson and Kieff, 1992a; Tomkin-
on et al., 1993a). The BamHI-C-AluI primers and the
am122 primers also have been described (Robertson
nd Kieff, 1995; Tomkinson et al., 1993b). The BamHI-C-
luI primers amplify a 157-bp fragment for both type 1
nd type 2 EBV; however, only the type 1 PCR product
an be digested with AluI into fragments of 52 and 105
p. The Bam122 primers produce a PCR product for both iype 1 and type 2 genomes. This PCR product contains a
amHI site in the type 1 DNA but not in type 2 DNA
Robertson and Kieff, 1995; Tomkinson et al., 1993b). Type
and type 2 EBNA2 PCR products were amplified using
common forward primer and type-specific reverse
rimers, which have also been previously described
Sample et al., 1990).
PCR and restriction endonuclease digestion. Crude
NA extracts were prepared for PCR by proteinase K
reatment of harvested cells. Cells from 0.5 ml of a
ell-growing culture were resuspended in 250 ml of 0.23
BS. This solution then was incubated with proteinase K
0.75 ng/ml) at 55°C for 1 h, followed by inactivation of the
nzyme at 95°C for another hour. Five microliters of
hese DNA solutions then were added to reaction com-
onents to give a 25-ml reaction mixture. The PCR was
arried out in 20 mM Tris–HCl (pH 8.4), 50 mM KCl, 1.5
M MgCl2, 0.5 mM of each deoxynucleotide triphos-
hate (dNTP), 0.1 mM of each primer, and 0.75 U of Taq
olymerase. DNA was amplified in an MJ Research, Inc.
hermal cycler machine. A total of 40 cycles was run,
ach consisting of 1 min at 94°C, 1 min at 58°C, and 1
in at 72°C. PCR-amplified DNA was analyzed by elec-
rophoresis in a 1% (wt/vol) ME-agarose, 2% (wt/vol)
uSieve agarose gel and stained with ethidium bromide.
or restriction endonuclease digestion, the entire PCR
eaction was precipitated in 100% ethanol and resus-
ended in 10 ml of 13 TE. The DNA then was digested
vernight in a 30-ml reaction mixture based on the en-
yme manufacturer’s protocol.
mmunoblot analysis
Harvested cells were dispersed mechanically and dis-
olved in SDS lysis buffer. To account for low levels of
xpression of viral proteins in BC-1 and BC-2 cell lines,
he number of harvested cells from these lines was
ncreased twofold (1,000,000 cells) as compared to the
umber harvested from B95-8, P3HR-1, and BJAB cell
ines (500,000 cells). Cell lysates were fractionated by 8%
odium dodecyl sulfate polyacrylamide gel electrophore-
is (SDS–PAGE), and proteins were transferred to
.45-mm Bio-Rad nitrocellulose membranes. The mem-
ranes were analyzed according to the manufacturer’s
rotocol and were incubated in the human serum dilu-
ions at 4°C overnight. ProteinA-HRP secondary antibody
as used at a 1:7500 dilution, and proteins were de-
ected using chemilluminescence reagents (Amersham).
mages were scanned into the computer and prepared
or publication using COREL DRAW.
outhern blot analysis
Cells were harvested and resuspended in TE buffer
ith 10% SDS. After digestion with proteinase K and
henol-chloroform extraction, the DNA was precipitatedn 100% ethanol and resuspended in TE buffer with
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368 AGUIRRE AND ROBERTSONNase (10 mg/ml). Total DNA (15 mg) of BC-1 and BC-2
nd 5 mg of total DNA of B95-8, P3HR-1, and BJAB were
igested with appropriate enzymes. After digestion, the
eactions were concentrated under vacuum, resus-
ended in stop buffer, and then run out on a 0.5% ME
garose gel in 0.53 TBE. The DNA was transferred to an
ctivated nylon membrane (GeneScreen Plus; New En-
land Nuclear). Membranes then were hybridized with
reviously described [32P]dCTP-labeled total EBV DNA
robes (Robertson et al.,1994).
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